Earnings ·
Reports Q4 loss of $0.18 per share and announces NDA submission for remibetadex
RFLRafael Holdings, Inc.
Rafael Holdings reported a net loss attributable to common stockholders of $9.2 million, or $0.18 per share, for the fourth quarter ended July 31, 2026, compared to a $12.1 million loss in the prior year period. Full-year fiscal 2026 results showed a net loss of $29.6 million, or $0.58 per share, versus $30.5 million in the previous year. The company also announced that its subsidiary, Cyclo Therapeutics, submitted a New Drug Application to the FDA for remibetadex (Trappsol® Cyclo™) to treat Niemann-Pick Disease Type C. Rafael Holdings is a biotechnology company that develops pharmaceuticals and holds interests in clinical-stage companies.